Procyanidin B3
Based on 1 publication(s) in Google Scholar
Procyanidin B3 is a natural product with antioxidant activity and oral bioavailability, possessing good blood-brain barrier penetration. Procyanidin B3 is a selective inhibitor of histone acetyltransferase (HAT). By inhibiting p300 HAT-mediated acetylation of the androgen receptor (androgen receptor). Procyanidin B3 alleviates intervertebral disc degeneration (IVDD) by inhibiting the formation of the TLR4/MD-2 complex. Procyanidin B3 can be used in research on prostate cancer and arthritis.
For research use only. We do not sell to patients.
- Purity: 99.92%
- CAS No.: 23567-23-9
- Formula: C30H26O12
- Molecular Weight:578.52
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Epigenetics Compound Library
HY-L005
-
Immunology/Inflammation Compound Library
HY-L007
-
Natural Product Library
HY-L021
-
Histone Modification Research Compound Library
HY-L024
-
Anti-Cancer Compound Library
HY-L025
-
CNS-Penetrant Compound Library
HY-L028
-
Small Molecule Immuno-Oncology Compound Library
HY-L031
-
Antioxidant Compound Library
HY-L037
-
Differentiation Inducing Compound Library
HY-L038
-
Lipid Compound Library
HY-L043
-
Oxygen Sensing Compound Library
HY-L045
-
Medicine Food Homology Compound Library
HY-L055
-
Phenols Library
HY-L057
-
Pyroptosis Compound Library
HY-L059
-
Orally Active Compound Library
HY-L061
-
Traditional Chinese Medicine Active Compound Library
HY-L065
-
Flavonoids Library
HY-L068
-
Anti-Obesity Compound Library
HY-L087
-
Transcription Factor-Targeted Library
HY-L090
-
Food-Sourced Compound Library
HY-L094
-
Anti-Cancer Natural Product Library
HY-L107
-
Anti-inflammatory Traditional Chinese Medicine Active Compound Library
HY-L114
-
Plant-Sourced Natural Product Library
HY-L115
-
Human Metabolite Library
HY-L123
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Nuclear Receptor Compound Library
HY-L126
-
Pain-Related Compound Library
HY-L139
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Autoimmune Disease Compound Library
HY-L156
-
Highly Selective Inhibitors Library
HY-L158
-
Multi-Target Compound Library
HY-L176
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
Natural Product Library Plus
HY-L021P
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Bioactive Compound Library
HY-L001
-
Anti-Fibrosis Compound Library
HY-L185
-
Miao Ethnicity Medicine Compound Library
HY-L190
-
Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library
HY-L194
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library
HY-L209
-
Anti-Rheumatic Arthritis Compound Library
HY-L210
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library
HY-L223
-
Diarrhea-Related Traditional Chinese Medicine Active Compound Library
HY-L224
-
Posttranslational Modification Library
HY-L226
-
Pattern Recognition Receptors Library
HY-L237
-
Mongolian Medicine Compound Library
HY-L238
-
Natural Product Diversity Scaffold Library
HY-L245
-
Lactylation Compound Library
HY-L249
-
Mass Spectrometry Natural Product Library
HY-L262
Publications Citing Use of MedChemExpress (MCE) Procyanidin B3
More
Biological Activity
|
CBP/p300 |
TLR4 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MT4 | CC50 |
117.8 μg/mL
Compound: 3, procyanidin B3
|
Cytotoxicity against human MT4 cells by MTT assay
Cytotoxicity against human MT4 cells by MTT assay
|
[PMID: 10425115] |
| MT4 | IC50 |
27 μg/mL
Compound: 3, procyanidin B3
|
Antiviral activity against HIV infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
Antiviral activity against HIV infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
|
[PMID: 10425115] |
Procyanidin B3 (50 and 100 μM, 1 h) inhibits the AR(androgen receptor)-dependent promoter activity induced by the synthetic androgen R1881 in LNCaP cells[1]. Procyanidin B3 (25-100 μM, 1 h) inhibits p300 HAT activity and p300-mediated AR (androgen receptor) acetylation in a dose-dependent manner in LNCaP cells[1]. Procyanidin B3 (50 μM, 12 hours) enhances the antagonistic effect of Flutamide (HY-B0022) by inhibiting p300 activity[1]. Procyanidin B3 (40 μM, 24 and 48 h) significantly upregulates the cell viability of human nucleus pulposus (NP) cells[4]. Procyanidin B3 (2.5-40 μM, 24 h) inhibits the inflammatory effects in human nucleus pulposus (NP) cells exposed to lipopolysaccharide (HY-D1056)[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human nucleus pulposus (NP) cells
-
Concentration:0, 1, 2.5, 10, 40, 160 μM
-
Incubation Time:24 h and 48 h
-
Result:Significantly up-regulated cell viability with 40 µmol/L for 24 and 48 hours.
-
Cell Line:Human LNCap
-
Concentration:50 and 100 μM
-
Incubation Time:1 h
-
Result:Inhibited the synthetic androgen R1881-induced AR-dependent promoter activity. Resulted in the transcription levels of NKX3.1 and PSA genes being reduced to levels similar to those with Flutamide (HY-B0022) treatment. Combined treatment with Flutamide (HY-B0022) increased the inhibition of p300-mediated AR transcription.
-
Cell Line:Human nucleus pulposus (NP) cells
-
Concentration:2.5, 10, 40 μM
-
Incubation Time:24 h
-
Result:Suppressed the expression levels of inflammation-related regulatory factors Cyclooxygenase-2 and Inducible Nitric Oxide Synthase. Reversed the Lipopolysaccharides (HY-D1056)-induced changes in NF-κB signaling pathway protein expression at the dose of 40 μM, including increased cytoplasmic IκBα expression and decreased nuclear p65 expression.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Lipopolysaccharides (HY-D1056)-induced IVDD (intervertebral disc degeneration) Sprague-Dawley rats model
-
Dosage:30 mg/kg
-
Administration:Oral gavage (p.o.),once daily for 4 weeks
-
Result:Prevented the loss of gelatin NP cells and structural damage of annulus fibrosus in IVDD rat model.
-
Animal Model:Surgically-induced osteoarthritis mice model[2]
-
Dosage:100 mg/kg
-
Administration:Oral gavage (p.o.), once daily, 5 days a week for 4 weeks
-
Result:Prevented aberrant articular cartilage degeneration and heterotopic cartilage formation through suppression of the nitric oxide synthase (iNOS).
Chemical Information
-
CAS No. 23567-23-9
-
Appearance Solid
-
Molecular Weight 578.52
-
Formula C30H26O12
-
Color White to light yellow
-
SMILES
O[C@@H]1[C@@H](C2=CC=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C3[C@H]1C4=C5C(C[C@H](O)[C@@H](C6=CC=C(O)C(O)=C6)O5)=C(O)C=C4O
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Food Chem
Flavonoid-mediated metabolic underpinning quality variation in red bud-sport pear mutants. [Abstract]2025 May 31:489:144992. PMID: 40466530
Solvent & Solubility
DMSO : 50 mg/mL (86.43 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.32 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.32 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (287 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Choi KC, et al. Procyanidin B3, an inhibitor of histone acetyltransferase, enhances the action of antagonist for prostate cancer cells via inhibition of p300-dependent acetylation of androgen receptor. Biochem J. 2011 Jan 1;433(1):235-44. [Content Brief]
[2]. Aini H, et al. Procyanidin B3 prevents articular cartilage degeneration and heterotopic cartilage formation in a mouse surgical osteoarthritis model[J]. PLoS One, 2012, 7(5): e37728. [Content Brief]
[3]. Mizuno M, et al. Synthesis and antioxidant activity of a procyanidin B3 analogue. Bioorg Med Chem Lett. 2017 Feb 15;27(4):1041-1044. [Content Brief]
[4]. Shang P, et al. Procyanidin B3 alleviates intervertebral disc degeneration via interaction with the TLR4/MD-2 complex. J Cell Mol Med. 2020 Mar;24(6):3701-3711. [Content Brief]
[5]. Mizuno M, et al. Inhibition of β-amyloid-induced neurotoxicity by planar analogues of procyanidin B3. Bioorg Med Chem Lett. 2019 Sep 15;29(18):2659-2663. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.7285 mL | 8.6427 mL | 17.2855 mL | 43.2137 mL |
| 5 mM | 0.3457 mL | 1.7285 mL | 3.4571 mL | 8.6427 mL | |
| 10 mM | 0.1729 mL | 0.8643 mL | 1.7285 mL | 4.3214 mL | |
| 15 mM | 0.1152 mL | 0.5762 mL | 1.1524 mL | 2.8809 mL | |
| 20 mM | 0.0864 mL | 0.4321 mL | 0.8643 mL | 2.1607 mL | |
| 25 mM | 0.0691 mL | 0.3457 mL | 0.6914 mL | 1.7285 mL | |
| 30 mM | 0.0576 mL | 0.2881 mL | 0.5762 mL | 1.4405 mL | |
| 40 mM | 0.0432 mL | 0.2161 mL | 0.4321 mL | 1.0803 mL | |
| 50 mM | 0.0346 mL | 0.1729 mL | 0.3457 mL | 0.8643 mL | |
| 60 mM | 0.0288 mL | 0.1440 mL | 0.2881 mL | 0.7202 mL | |
| 80 mM | 0.0216 mL | 0.1080 mL | 0.2161 mL | 0.5402 mL |
Powered by Bioz